The price-to-earnings ratio for Idexx Laboratories, Inc (NASDAQ: IDXX) is above average at 40.88x, Company’s 36-month beta value is 1.37.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for IDXX is 81.07M, and currently, short sellers hold a 1.85% ratio of that floaft. The average trading volume of IDXX on January 17, 2025 was 648.26K shares.
IDXX) stock’s latest price update
Idexx Laboratories, Inc (NASDAQ: IDXX)’s stock price has gone decline by -1.13 in comparison to its previous close of 428.62, however, the company has experienced a 1.37% increase in its stock price over the last five trading days. businesswire.com reported 2025-01-16 that WESTBROOK, Maine–(BUSINESS WIRE)–IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2024 Earnings Snapshot through a link on.
IDXX’s Market Performance
IDXX’s stock has risen by 1.37% in the past week, with a monthly drop of -1.56% and a quarterly drop of -8.65%. The volatility ratio for the week is 2.73% while the volatility levels for the last 30 days are 2.62% for Idexx Laboratories, Inc The simple moving average for the past 20 days is 1.32% for IDXX’s stock, with a -10.21% simple moving average for the past 200 days.
Analysts’ Opinion of IDXX
Many brokerage firms have already submitted their reports for IDXX stocks, with Leerink Partners repeating the rating for IDXX by listing it as a “Outperform.” The predicted price for IDXX in the upcoming period, according to Leerink Partners is $500 based on the research report published on December 02, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see IDXX reach a price target of $580. The rating they have provided for IDXX stocks is “Buy” according to the report published on July 25th, 2024.
Piper Sandler gave a rating of “Neutral” to IDXX, setting the target price at $525 in the report published on January 30th of the previous year.
IDXX Trading at -0.09% from the 50-Day Moving Average
After a stumble in the market that brought IDXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.36% of loss for the given period.
Volatility was left at 2.62%, however, over the last 30 days, the volatility rate increased by 2.73%, as shares sank -0.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.39% upper at present.
During the last 5 trading sessions, IDXX rose by +1.53%, which changed the moving average for the period of 200-days by -18.64% in comparison to the 20-day moving average, which settled at $418.27. In addition, Idexx Laboratories, Inc saw 2.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDXX starting from Vandebroek Sophie V., who sale 344 shares at the price of $420.44 back on Nov 27 ’24. After this action, Vandebroek Sophie V. now owns 905 shares of Idexx Laboratories, Inc, valued at $144,630 using the latest closing price.
Vandebroek Sophie V., the Director of Idexx Laboratories, Inc, proposed sale 344 shares at $420.44 during a trade that took place back on Nov 27 ’24, which means that Vandebroek Sophie V. is holding shares at $144,630 based on the most recent closing price.
Stock Fundamentals for IDXX
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.61 for the gross margin
The net margin for Idexx Laboratories, Inc stands at 0.23. The total capital return value is set at 0.48. Equity return is now at value 59.42, with 26.91 for asset returns.
Based on Idexx Laboratories, Inc (IDXX), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at 0.92. The debt to equity ratio resting at 0.62. The interest coverage ratio of the stock is 33.78.
Currently, EBITDA for the company is 1.22 billion with net debt to EBITDA at 0.55. When we switch over and look at the enterprise to sales, we see a ratio of 9.21. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 1.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.36.
Conclusion
In a nutshell, Idexx Laboratories, Inc (IDXX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
